PC planned antiviral proteins restrain COVID-19 in lab, researchers find Kumar Jeetendra | September 14, 2020 Computer-designed synthetic antiviral proteins have been shown to protect lab-grown human cells from SARS-CoV-2, the coronavirus that causes COVID-19, scientists say. From the experiments, the lead antiviral candidate, called LCB1, rivalled the best-known SARS-CoV-2 neutralising antibodies in its protective activities, according to the findings published in the journal Science. The researchers at the University of …
Asia offers more influenza shots to take off COVID-19 difficulties Kumar Jeetendra | September 14, 2020 Some Asian countries are rolling out early and more competitive influenza vaccination programs this year, seeking to decrease the capacity of people contracting the flu and COVID-19 simultaneously, crippling health care systems. With a second or third wave of the coronavirus pandemic looming for many countries, tackling this year’s flu season – typically December through …
DCGI orders Serum Institute of India to suspend enrollment for Oxford COVID-19 immunization preliminaries Kumar Jeetendra | September 12, 2020 Drugs Controller General of India (DCGI) has led Serum Institute of India to suspend until further orders new recruitment in stage 2 and 3 clinical trials of the Oxford COVID-19 vaccine candidate in the backdrop of pharma giant AstraZeneca pausing the trials in different countries. In an order, a copy of which was obtained by …
Bharat Biotech States Covaxin generated Strong immune response in monkeys Kumar Jeetendra | September 12, 2020 Bharat Biotech announced its prospective COVID-19 vaccine — Covaxin — was discovered to generate strong immune responses in rhesus macaques or monkeys, preventing infection and disease even upon high levels of exposure to live SARS-CoV-2 virus. The Hyderabad-based firm said data from the study on primates substantiate the immunogenicity of the vaccine candidate. Covaxin developed …
Dr. U S Vishal Rao shares deeper insights into the ICMR PLACID trial research on plasma therapy Kumar Jeetendra | September 11, 2020 Bengaluru, 11th September 2020 – The recent study conducted by the Indian Council of Medical Research (ICMR) stated that using plasma therapy for COVID-19 claims that the therapy neither reduces the death risk nor does it slow down the disease’s progression from mild to severe stage. HealthCare Global Enterprises Limited (HCG) – largest cancer care …
Study surveys ongoing bits of knowledge into the pathogenesis of feline leukemia virus contamination Kumar Jeetendra | September 10, 2020 Feline leukemia virus (FeLV) is a gammaretrovirus that occurs worldwide in domestic cats, in addition to small wild cats. It’s associated with various severe, and sometimes fatal, diseases including anaemia, immunosuppression and certain cancers. First described over 55 years ago, FeLV has been the topic of intense research interest, which has led to increasingly robust …
China favors first nasal spray COVID-19 antibody for preliminaries Kumar Jeetendra | September 10, 2020 China has approved for trials its initial nasal spray vaccine to combat the novel coronavirus that has claimed over 904,000 lives and infected more than 27 million people globally, official media here reported on September 10. China’s only nasal spray vaccine against the coronavirus is anticipated to start phase I clinical trials in November, and …
CRISPR-based framework smothers qualities identified with AAV antibody production Kumar Jeetendra | September 9, 2020 Gene therapy generally is based on viruses, such as adeno-associated virus (AAV), to deliver genes into a cell. In the event of CRISPR-based gene therapies, molecular scissors can then snip out a faulty gene, add in a missing arrangement or enact a temporary change in its expression, but the body’s immune response to AAV can …
Novel medication could improve future and quality for patients with difficult to-treat malignant growths Kumar Jeetendra | September 9, 2020 The Sheffield researchers founded the spin-out Modulus Oncology with a group of experienced biotech entrepreneurs to fast-track the drug into clinical testing over two decades. The researchers founded the spin-out firm Modulus Oncology, along with a team of seasoned biotech entrepreneurs, to fast-track the drug into clinical testing over two years. The Sheffield team made …
Brazil eyes Covid antibody rollout in January: Minister Kumar Jeetendra | September 9, 2020 Brazil’s acting Health Minister Eduardo Pazuello stated on Tuesday that a COVID-19 vaccine could be rolled out for all Brazilians in January 2021. “We’re closing contracts with vaccine manufacturers and the forecast is that a vaccine will arrive for us starting in January next year and we will begin vaccinating everybody,” Eduardo Pazuello said in …
Russia delivers first group of Sputnik V for open: Report Kumar Jeetendra | September 8, 2020 Russia has released the first batch of COVID-19 vaccine, called Sputnik V, into civil movement and the supplies of the medication to the Russian regions are expected soon, said a report citing Russian Health Ministry. The Russian health ministry enrolled the first vaccine against COVID-19, developed by Gamaleya National Research Center of Epidemiology and Microbiology …
Russia finishes early preliminaries of second potential COVID-19 immunization: Report Kumar Jeetendra | September 8, 2020 Siberia’s Vector virology institute on September 8 finished early-stage human trials, called Phase II, of a second possible Russian vaccine against COVID-19, the state consumer safety watchdog was cited by the Interfax news agency as saying. Russia registered its first vaccine candidate, developed by Moscow’s Gamaleya Institute, in August after finishing early-stage human trials. “Today… …
